Muhammad Anis Haider

🚨 IVUS ≠ better outcomes (in expert hands) in LM or CHIP ⏱️ Faster 💰 Cheaper 📊 Same outcomes Angio done right = enough 👏 Strong work 👏🏼 DOI: 10.1056/NEJMoa2601521 DOI: 10.1056/NEJMoa2600440 #CardioTwitter #InterventionalCardiology #PCI #IVUS #CHIPPCI #LeftMainPCI #ClinicalTrials #EvidenceBasedMedicine #TCT #ACC

🚨Built for shock → works in shock Not for routine prophylactic use. Hats off to all investigators—practice-changing evidence for better care👏🏼👏🏼👏🏼

Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26 jacc.org/doi/10.1016/j.…

Honored to present at ACC 2026—turning a high-risk complication into a controlled percutaneous solution. Mar 29 | 2–3 PM #ACC2026 , #CardioTwitter, #TAVR, #StructuralHeart, #LAAO @midamericaheart @chetanhuded @SanjayaKGupta1

CLOSURE-AF ⛔️⚠️ Pause. Interpret carefully. Device failure… or procedural artifact? CLOSURE-AF — •Fails noninferiority, yet stroke ≈ identical → signal = bleeding + death, not embolic failure •Bleeding ↑ with LAAC → largely early/periprocedural → technique & strategy signal •Discordant with prior RCTs (PROTECT-AF, PREVAIL, PRAGUE-17, OPTION) → LAAC ≈ noninferior ± ↓ late bleeding •Modern DOAC comparator → LAAC benefit is delayed, early hazard amplified •Composite endpoint + underpowered components → driver of harm unclear nejm.org/doi/full/10.10… #EPeeps #CardioTwitter #AtrialFibrillation #LAAO #LAAC #Watchman #Amulet #StrokePrevention #StructuralHeart @NEJM @DFCapodanno @drjohnm @djc795 #TCT2026 #EUROPCR

🥸One of the best articles on CV physiology with aging 😱 Congratulations to the authors and reviewers: 👇👇👇

@realarainmd @stefan_harb @rajivxgulati @aymanka @agtruesdell @SripalBangalore @RinfretStephane @rickytiago @evandrofilhobr @Hragy @DocSavageTJU @djc795 @mirvatalasnag @SanjogKalra @mmamas1973 @jedicath @SarahFairley7 @saraceciliamtz @ShariqShamimMD @DrDarshanDoshi 🙌🏾👏🏼👏🏼🙏🏽

@stefan_harb @rajivxgulati @aymanka @agtruesdell @SripalBangalore @RinfretStephane @rickytiago @evandrofilhobr @Hragy @DocSavageTJU @djc795 @mirvatalasnag @SanjogKalra @mmamas1973 @jedicath @SarahFairley7 @saraceciliamtz @ShariqShamimMD @DrDarshanDoshi If you look closely, the diagonal came back - after we painstakingly rescued it. 😅 As @MAnisHaider astutely noted, the heart rate picked up with the IMH and loss of the diagonal. It didn’t return to normal until after the diagonal had flow again.

Now You See It, Now You Don’t! 😳🤔😀 70 M with AW MI last summer. Referred for proximal LAD #CTOPCI. Our #contrast1st injection showed a microchannel → #HDR not needed! We crossed with an XT and an MG. What is going on with the LAD here? 🧐 Poll below. Comments welcome!

Great teaching as usual. 🙏🏽🙌🏾 Looking at angio, it seems few things were responsible possibly: 1- Small dissection flap 2- Pain causing Tachycardia reducing coronary flow as evident in the angio 3- final angio demonstrating slower heart rate which cause increased coronary flow and like lifted up the dissection flap spontaneously. But I am not sure how his HR slowed down if you didn't give anything? Waiting for the mystery resolution 😀

Great teaching as usual. 🙏🏽🙌🏾 Looking at angio, it seems few things were responsible possibly: 1- Small dissection flap 2- Pain causing Tachycardia reducing coronary flow as evident in the angio 3- final angio demonstrating slower heart rate which cause increased coronary flow and like lifted up the dissection flap spontaneously. But I am not sure how his HR slowed down if you didn't give anything? Waiting for the mystery resolution 😀

👆🏼 Poll question above! @rajivxgulati @aymanka @agtruesdell @stefan_harb @SripalBangalore @RinfretStephane @rickytiago @evandrofilhobr @Hragy @DocSavageTJU @djc795 @mirvatalasnag @SanjogKalra @mmamas1973 @jedicath @SarahFairley7 @saraceciliamtz @ShariqShamimMD @DrDarshanDoshi @NishithChandra @aspergian1 @SaidAshrafMD @MichaelMegalyMD @mornei2011 @DrIHHashmi1 @TariqShafiDr @abadkhan2002 @gbiondizoccai @TWilsonMD @jl35wilsonMD

ViV-TAVR in failed small surgical valves (≤23 mm): what matters at 3 years? The randomized LYTEN trial 3-year follow-up shows a clear hemodynamic signal: supra-annular SEV (Evolut R/PRO/PRO+) outperform BEV (SAPIEN 3/ULTRA) with significantly lower gradients and larger EOAs—yet clinical outcomes remain similar (death, stroke, HF hospitalization). So what should drive ViV strategy in small valves? Not a single metric. Hemodynamics, operator experience with BVF, future coronary access, and lifetime management all matter—and demand case-by-case individualization. Key limitations • Not powered for clinical endpoints • ~20% missing 3-year echo follow-up • Events not independently adjudicated; ascertainment not blinded • BVF at operator discretion; heterogeneous surgical valve types Notably, BVF technique has matured substantially—with major contributions from the St. Luke’s Mid America Structural Heart Team,#StLukesMidAmerica redefining what’s achievable in small-valve ViV. #ViVTAVR #StructuralHeart #AorticStenosis #SmallValve #PPM #BVF #LifetimeManagement #CoronaryAccess #HeartTeam #StLukesMidAmerica #europcr lnkd.in/gCPUXE9R

Use LV angiogram when you suspect mechanical complications in AMI

Congratulations to the entire author group on this important and thoughtfully executed study. As a trainee, it is truly an honor to work with and learn from such exceptional mentors and innovators. The findings meaningfully inform valve sizing and inflation strategies to improve predictability and safety in TMViR. Heart: doi.org/10.1016/j.shj.… #StructuralHeart #TMVR #ValveInRing #TranscatheterTherapies #MitralValve #HeartTeam #InnovationInCardiology #SaintLuke’sMidAmericaHeartInstitute Mid America Heart Institute

Are we disciplined enough with PD sizing in daily TAVR practice? Useful insight from bench testing by Prof Ole De Backer and his team. Post-dilatation is not benign: especially beyond IFU. Bench testing of Evolut FX+ shows: • IFU-guided PD preserved leaflet integrity and performance through 200M cycles (~5-year equivalent) • Off-guidance balloon oversizing caused leaflet tears, typically at the leaflet–skirt/frame interface Takeaway: gradient optimization must be balanced against durability—PD is a dose problem (balloon size × compliance × pressure). Question: Is it time for annulus-conformal / valve-waisted PD balloons that target PVL while protecting the Evolut waist and leaflet attachment zone? #medtronik #TAVR #StructuralHeart #ValveDurability #InterventionalCardiology #Hemodynamics @PCRonline lnkd.in/g3qkDq6A

Post-TAVR gradients matter—long after discharge. Important long-term data, but key caveats remain: • Single valve platform → limited generalisability • Early-era cohort (≤2014) → first-generation valves; relevance to modern TAVR uncertain • Residual confounding → valve sizing, small annuli, PPM not fully separated • No mechanistic imaging → no systematic CT for HALT, leaflet thickening, expansion • Doppler-centric SVD definition → gradients without consistent EOA data • Site-reported echo → no core-lab adjudication With mounting evidence linking residual gradients to durability and outcomes, the key question is: Is aggressive gradient optimisation—perhaps even routine double-TAP—the next paradigm in everyday TAVR practice? #TAVR #StructuralHeart #ValveDurability #InterventionalCardiology #StructuralValveDeterioration #HeartValveDisease #EuroIntervention

NAVULTRA registry: in patients with small aortic annuli, intra-annular Navitor and SAPIEN 3 Ultra showed comparable 1-year clinical outcomes. Navitor delivered superior haemodynamics with less PPM, but more mild PVL and pacemaker implantation. #TAVI #StructuralHeart #Cardiology eurointervention.pcronline.com/article/intra-… @drnvanmieghem @didier_tchetche @BuccheriSergio @luisnombela @barbanti_marco @EmanueleBarba13 @drmaisano @lulic_d @kiadeb87 @MCasenghi @ClaraFdezCordon @AmandaSherwen @nbuzzatti @tambucor @azeemlatib

First case completed with SavvyWire™ — great teamwork and a smooth learning curve. Exciting to see how new technology continues to advance TAVR practice. #TAVR #StructuralHeart #SavvyWire #MedTech #CathLab #Cardiology @akcmahi @chetanhuded @MidAmericaHeart @EdwardsLifesci #TeamSaintLukes

My Toolkit 🧰⚙️🪛: How to close vascular access with a combined suture-/plug-based strategy using one ProStyle and one Angio-Seal in TAVI 🔗pcronline.com/Cases-resource… Large-bore femoral access closure remains a critical step in transfemoral #TAVI, where access-site complications can significantly impact outcomes. @akiko704 & @kiadeb87 share a step-by-step tutorial on a combined suture- and plug-based closure strategy Reviewed by Moritz Seiffert. #interventionalcardiology #CardioEd #TAVR

🎯Fully percutaneous transseptal mitral chordal replacement 🧵 💫A new step forward in mitral repair innovation @RodrigoEstvez1 @manuelbarreirop @m_taramasso @jabazal

The top ten impactful papers from 2025 on tricuspid intervention we almost missed! 🔗pcronline.com/News/Whats-new… Transcatheter interventions have rapidly reshaped the management of tricuspid valve disease, with landmark trials establishing feasibility and early clinical benefit. Beyond these pivotal studies, a series of less visible but highly informative papers addressed mechanisms, complications, patient phenotypes, and unintended consequences of intervention. Read this review by @Sticchi_Alex #PCRTricuspid #TreatTR #FixTR #interventionalcardiology